| Name | Pruitthealth - Forsyth |
|---|---|
| Location | 521 Cabiness Road, Forsyth, Georgia |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 72 |
| Occupancy Rate | 70.97% |
| Medicare ID (CCN) | 115418 |
| Legal Business Name | Pruitthealth Forsyth Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1154378677 |
| Organization Name | PRUITTHEALTH - FORSYTH, LLC |
| Doing Business As | PRUITTHEALTH - FORSYTH |
| Address | 521 Cabaniss Rd, Forsyth, GA 31029 |
| Phone Number | 478-994-5671 |
News Archive
A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART).
Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer's disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society.
BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced the European launch of its new, unified platform pacemaker series, Evia, and several new products to further strengthen its bradycardia portfolio.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART).
Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer's disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society.
BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced the European launch of its new, unified platform pacemaker series, Evia, and several new products to further strengthen its bradycardia portfolio.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 29.63 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.4 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 41.67 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 4.32 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.24 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 3.89 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.59 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.45 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.41 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 82.18 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.89 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 42.74 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.86 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.16 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.24 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 73.45 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 75.79 | 82.93 |
News Archive
A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART).
Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer's disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society.
BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced the European launch of its new, unified platform pacemaker series, Evia, and several new products to further strengthen its bradycardia portfolio.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age.
› Verified 5 days ago